188 related articles for article (PubMed ID: 22147690)
1. Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.
Hutt M; Färber-Schwarz A; Unverdorben F; Richter F; Kontermann RE
J Biol Chem; 2012 Feb; 287(7):4462-9. PubMed ID: 22147690
[TBL] [Abstract][Full Text] [Related]
2. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
[TBL] [Abstract][Full Text] [Related]
3. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
[TBL] [Abstract][Full Text] [Related]
4. A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
Unverdorben F; Hutt M; Seifert O; Kontermann RE
PLoS One; 2015; 10(10):e0139838. PubMed ID: 26430884
[TBL] [Abstract][Full Text] [Related]
5. Half-life extension of porcine interferon-α by fusion to the IgG-binding domain of streptococcal G protein.
Zong Y; Tan X; Xiao J; Zhang X; Xia X; Sun H
Protein Expr Purif; 2019 Jan; 153():53-58. PubMed ID: 30165247
[TBL] [Abstract][Full Text] [Related]
6. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
7. GlycoTAIL and FlexiTAIL as Half-Life Extension Modules for Recombinant Antibody Fragments.
Seifert O; Kontermann RE
Molecules; 2022 May; 27(10):. PubMed ID: 35630749
[TBL] [Abstract][Full Text] [Related]
8. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
Stork R; Müller D; Kontermann RE
Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
[TBL] [Abstract][Full Text] [Related]
9. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
[TBL] [Abstract][Full Text] [Related]
10. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life.
Schlapschy M; Theobald I; Mack H; Schottelius M; Wester HJ; Skerra A
Protein Eng Des Sel; 2007 Jun; 20(6):273-84. PubMed ID: 17595342
[TBL] [Abstract][Full Text] [Related]
11. Glycoengineering approach to half-life extension of recombinant biotherapeutics.
Chen C; Constantinou A; Chester KA; Vyas B; Canis K; Haslam SM; Dell A; Epenetos AA; Deonarain MP
Bioconjug Chem; 2012 Aug; 23(8):1524-33. PubMed ID: 22681552
[TBL] [Abstract][Full Text] [Related]
12. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of a (67)Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag).
Morais M; Cantante C; Gano L; Santos I; Lourenço S; Santos C; Fontes C; Aires da Silva F; Gonçalves J; Correia JD
Nucl Med Biol; 2014 May; 41 Suppl():e44-8. PubMed ID: 24530366
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.
Unverdorben F; Richter F; Hutt M; Seifert O; Malinge P; Fischer N; Kontermann RE
MAbs; 2016; 8(1):120-8. PubMed ID: 26514880
[TBL] [Abstract][Full Text] [Related]
15. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
16. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
17. Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins.
Graille M; Stura EA; Housden NG; Beckingham JA; Bottomley SP; Beale D; Taussig MJ; Sutton BJ; Gore MG; Charbonnier JB
Structure; 2001 Aug; 9(8):679-87. PubMed ID: 11587642
[TBL] [Abstract][Full Text] [Related]
18. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.
Schneider B; Münkel S; Krippner-Heidenreich A; Grunwald I; Wels WS; Wajant H; Pfizenmaier K; Gerspach J
Cell Death Dis; 2010 Aug; 1(8):e68. PubMed ID: 21364672
[TBL] [Abstract][Full Text] [Related]
20. Strategies to extend plasma half-lives of recombinant antibodies.
Kontermann RE
BioDrugs; 2009; 23(2):93-109. PubMed ID: 19489651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
